New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 23, 2012
16:25 EDTWMT, K, RDEA, AZN, BKS, ACHN, OTT, TWCOn The Fly: Closing Wrap
Stocks on Wall Street were lower following a pair of political developments in Europe. France’s incumbent president, Nicolas Sarkozy, came in second in the first round of the nation's elections and the Dutch cabinet failed to gain approval for a budget which included austerity measures, leading to their resignations. The European news, along with some disappointing data there and from China, weighed on the futures, which in turn led to a sharply lower open for the broader market. The market continued to move lower in the first hour of trading but then found a level where it began to build. The averages moved in a generally upward trend for the remainder of the session, as investors waited for the next round of earnings reports and for news later this week from the FOMC... ECONOMIC EVENTS: Domestically, little economic data of note was reported. Internationally, Markit's European composite purchase managers' index fell to 47.4 points while a flash Chinese PMI reading rose to 49.1 in April, with both of those figures signaling contraction... COMPANY NEWS: The New York Times said Wal-Mart (WMT) attempted to cover up bribery that it discovered at Wal-Mart de Mexico (WMMVY) and the retailers' shares were the Dow's worst performer, falling $2.91, or 4.66%, to $59.54... Kellogg (K) cut its full-year guidance as it said Europe's challenges were "more significant" than it expected and it sees Q1 challenges in some categories in the U.S. Shares sank $3.29, or 6.09%, to $50.70... MAJOR MOVERS: Among the notable gainers were Ardea Biosciences (RDEA), up $10.78, or 51.73%, to $31.62, after AstraZeneca (AZN) agreed to acquire the company for $32 per share, and Barnes & Noble (BKS), up $2.07, or 18.25%, to $13.41, as CNBC reported that Jana Partners is increasing its stake in the company to about 12%. Noteworthy losers included Achillion (ACHN), down $1.53, or 18.54%, to $6.74, following the company's report of Phase II study data for its lead hepatitis C treatment, and Otelco (OTT), down $5.37, or 44.64%, to $6.66, after it said Time Warner Cable (TWC) will not renew its existing contract for wholesale network connections, which made up almost 12% of Otelco’s consolidated revenue last year... INDICES: The Dow fell 102.09, or 0.78%, to 12,927.17; the Nasdaq dropped 30.00, or 1.00%, to 2,970.45; and the S&P 500 shed 11.59, or 0.84%, to 1,366.94.
News For WMT;K;RDEA;AZN;BKS;ACHN;OTT;TWC From The Last 14 Days
Check below for free stories on WMT;K;RDEA;AZN;BKS;ACHN;OTT;TWC the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
August 15, 2014
09:10 EDTACHNOn The Fly: Pre-market Movers
Subscribe for More Information
07:38 EDTTWCComcast met with FCC this week to argue for deal, NY Post says
Subscribe for More Information
07:11 EDTACHNAchillion achieves 100% SVR4 in Phase 2 trial of ACH-3102 and sofosbuvir
Achillion Pharmaceuticals announced interim results from an ongoing Phase 2 proxy study evaluating ACH-3102, Achillion's second-generation NS5A inhibitor, in combination with sofosbuvir, without ribavirin, for eight weeks of treatment in patients with treatment-naïve genotype 1 chronic hepatitis C virus infection. Of the 12 patients treated, 100 percent remained HCV RNA undetectable four weeks after completing therapy. Based upon these results, 12 additional patients will begin treatment with six weeks of once daily ACH-3102 and sofosbuvir. "ACH-3102 continues to demonstrate good safety and tolerability through three Phase 2 studies. We believe these studies also confirm a differentiated efficacy profile for an NS5A inhibitor. Achieving 100% SVR4 with eight weeks of treatment with sofosbuvir serving as a nucleotide proxy indicate that dosing 50 mg once daily of ACH-3102 plus a nucleotide inhibitor has the potential to achieve commercially competitive results for curing HCV in a short duration, ribavirin-free doublet," commented David Apelian, EVP and Chief Medical Officer at Achillion. Milind Deshpande, President and CEO of Achillion commented, "As we continue to achieve clinical milestones, we remain focused on execution of the broader clinical development strategy for our HCV portfolio. We expect that Phase 1 proof-of-concept results with ACH-3422 will be reported during the fall of this year, which we anticipate will lead to the start of a Phase 2 combination program to evaluate our proprietary doublet regimen for an eight week, or potentially shorter, treatment regimen for HCV that will begin before the end of 2014."
06:17 EDTACHNAchillion initiated with an Outperform at FBR Capital
Subscribe for More Information
August 14, 2014
19:59 EDTWMTWal-Mart sees rise in DVD orders following Disney, Amazon feud, Bloomberg says
Wal-Mart's (WMT) online division has capitalized on a feud between Disney (DIS) and Amazon (AMZN) by offering discounted pre-orders on Walt Disney DVDs, according to Bloomberg. Wal-Mart pre-orders of "Captain America" have increased by 90%, while orders of other Disney DVDs have increased by 40%, Bloomberg added, citing an e-mail from Wal-Mart spokesman Dan Toporek. Reference Link
17:53 EDTWMTWal-Mart not a bargain, Barron's reports
Wal-Mart reported in-line quarterly results, but lowered its FY15 EPS view due to investments in e-commerce and higher U.S. health-care costs. The stock trades for approximately 13 times forward earnings, but only has an 8% long-term earnings growth rate, roughly half the industry average. At current levels, the stock is no bargain, Barron's reports. Reference Link
17:08 EDTTWCSoros Fund Management gives quarterly update on stakes
NEW STAKES: CONSOL Energy (CNX), Google (GOOG), Level 3 (LVLT), Time Warner (TWC), and New Oriental (EDU). INCREASED STAKES: YPF SA (YPF), Apple (AAPL), Facebook (FB), AIG (AIG), and American Airlines (AAL). DECREASED STAKES: Teva (TEVA), Liberty Global (LBTYK), Barrick Gold (ABX), EQT (EQT), and Comcast (CMCSA). LIQUIDATED STAKES: FedEx (FDX), Monster Beverage (MNST), Google (GOOGL), Devon Energy (DVN), Marathon Petroleum (MPC).
16:30 EDTWMTOn The Fly: Closing Wrap
Subscribe for More Information
15:47 EDTWMTWal-Mart price target lowered to $80 from $84 at RW Baird
Subscribe for More Information
12:30 EDTWMTOn The Fly: Midday Wrap
Subscribe for More Information
12:01 EDTAZNThird Point gives quarterly update on stakes
NEW STAKES: Rackspace (RAX), Finisar (FNSR), Amgen (AMGN), Ally Financial (ALLY), and AstraZeneca (AZN). INCREASED STAKES: Dollar General (DG) and Dow Chemical (DOW). DECREASED STAKES: FedEx (FDX), Hertz (HTZ), T-Mobile (TMUS) and Intrexon (XON). LIQUIDATED STAKES: Google Class A (GOOGL), Verizon (VZ) and Mondelez (MDLZ).
08:16 EDTWMTWal-Mart lowers FY15 e-commerce sales growth forecast to 25%
"E-commerce is particularly important to both our customers and our company’s future, and we will continue to invest in areas such as technology, talent, and fulfillment. As a result, our fiscal 2015 earnings per share now assumes 5c-7c of incremental investment, versus our prior guidance of 2c-4c. I would like to add that, although we are slightly revising our e-commerce sales growth to 25% for this year, we continue to be very encouraged by the progress we are making on our strategic goals," Charles Holley, Walmart’s CFO, stated on the company's earnings conference call earlier.
07:30 EDTWMTWal-Mart reports Q2 U.S. comp traffic down 1.1%, average ticket up 1.1%
Subscribe for More Information
07:30 EDTWMTWal-Mart says saw double-digit e-commerce growth in 4 'most important' markets
Wal-Mart saw double-digit e-commerce growth from its "four most important markets," the U.S., U.K., China and Brazil, in Q1, Wal-Mart President and CEO Doug McMillon stated on the company's Q2 earnings call.
07:22 EDTWMTWal-Mart to hold a summit
2nd Annual U.S. Manufacturing Summit is being held in Denver, Colorado on August 14 at 4 pm. Webcast Link
07:10 EDTWMTWal-Mart CEO says pleased with 'solid' EPS, encouraged by e-commerce growth
Subscribe for More Information
07:07 EDTWMTWal-Mart sees Q3 EPS $1.10-$1.20, consensus $1.18
Subscribe for More Information
07:06 EDTWMTWal-Mart reports Q2 U.S. SSS flat
Subscribe for More Information
07:05 EDTWMTWal-Mart lowers FY15 EPS view to $4.90-$5.15 from $5.10-$5.45, consensus $5.15
Subscribe for More Information
07:02 EDTWMTWal-Mart reports Q2 EPS $1.21, consensus $1.21
Subscribe for More Information
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use